PRNewsWire
22 Oct 2025, 00:25 UTC · 48w ago
Verdict
Headline takes no side. We score 01801 +0.90 across four claims — strongly bullish.
+0.90strongly bullish
More positive than 96% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Innovent Biologics and Takeda have entered a global strategic partnership to develop and commercialize three next-generation cancer therapies (IBI363, IBI343, and IBI3001).
More positive than 93% of claims this week
The partnership includes a specific cost-sharing (40/60) and profit-sharing agreement for the global development and U.S. commercialization of the Phase 3 asset IBI363.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 79% of claims this week
Takeda explicitly stated that IBI363 and IBI343 have the potential to significantly enhance the company's growth potential post-2030.
More positive than 66% of claims this week
IBI363 has received Breakthrough Designation from the China NMPA and Fast Track Designation from the U.S. FDA for second-line sqNSCLC.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 96% of ticker scores this week
Innovent entered a strategic global partnership with Takeda to accelerate the development and commercialization of its next-gen oncology pipeline.
More positive than 88% of ticker scores this week
Takeda is gaining access to promising next-generation IO and ADC therapies that have the potential to significantly enhance its growth potential post-2030.
More positive than 88% of ticker scores this week
Takeda is gaining access to promising next-generation IO and ADC therapies that have the potential to significantly enhance its growth potential post-2030.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
—
No price for 01801 right now — the quote feed didn't answer.
01801 chart →
